• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Bruce E. Johnson, M.D.

Publications

  • Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB.Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer.Int J Radiat Oncol Biol Phys. 2014 May 24.
    24867533
  • Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.JAMA. 2014 May 21;311(19):1998-2006.
    24846037
  • Nishino M, Hatabu H, Johnson BE, McLoud TC.State of the art: response assessment in lung cancer in the era of genomic medicine.Radiology. 2014 Apr;271(1):6-27.
    24661292
  • Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.Cancer Res. 2013 Nov 15;73(22):6770-9.
    24063894
  • Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V.ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.J Clin Oncol. 2013 Nov 1;31(31):3926-34.
    24101054
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.Cancer. 2013 Nov 1;119(21):3761-8.
    23922022
  • Brunner AM, Costa DB, Heist RS, Garcia E, Lindeman NI, Sholl LM, Oxnard GR, Johnson BE, Hammerman PS.Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.J Thorac Oncol. 2013 Nov;8(11):1434-7.
    24128713
  • Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.Clin Cancer Res. 2013 Aug 15;19(16):4532-40.
    23833300
  • Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.J Thorac Oncol. 2013 Aug;8(8):1059-68.
    23787800
  • Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.AJR Am J Roentgenol. 2013 Jul;201(1):W64-71.
    23789698
  • Cardarella S, Johnson BE.Meta-Analysis of EGFR Kinase Inhibitors: Not Always Greater Than the Sum of Its Parts.Journal of the National Cancer Institute. 2013 Apr 17.
    23594425
  • Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.Cancer. 2013 Apr 5.
    23564469
  • Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.Lung Cancer. 2013 Mar;79(3):283-8.
    23254265
  • Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.J Thorac Oncol. 2013 Feb;8(2):179-84.
    23328547
  • Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.The introduction of systematic genomic testing for patients with non-small-cell lung cancer.J Thorac Oncol. 2012 Dec;7(12):1767-74.
    23154547
  • Shinagare AB, Okajima Y, Oxnard GR, Dipiro PJ, Johnson BE, Hatabu H, Nishino M.Unsuspected pulmonary embolism in lung cancer patients: Comparison of clinical characteristics and outcome with suspected pulmonary embolism.Lung Cancer. 2012 Nov;78(2):161-6.
    22959241
  • Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, Collisson EA, Cope L, Creighton CJ, Getz G, Herman JG, Johnson BE, Kucherlapati R, Ladanyi M, Maher CA, Robertson G, Sander C, Shen R, Sinha R, Sivachenko A, Thomas RK, Travis WD, Tsao MS, Weinstein JN, Wigle DA, Baylin SB, Govindan R, Meyerson M.Comprehensive genomic characterization of squamous cell lung cancers.Nature. 2012 Sep 27;489(7417):519-25.
    22960745
  • Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE.Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.J Thorac Oncol. 2012 Oct;7(10):1594-601.
    22968184
  • Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansén S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Jänne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.Cell. 2012 Sep 14;150(6):1107-20.
    22980975
  • Heon S, Johnson BE.Adjuvant chemotherapy for surgically resected non-small cell lung cancer.J Thorac Cardiovasc Surg. 2012 Sep;144(3):S39-42.
    22502967
  • Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.Clin Cancer Res. 2012 Aug 15;18(16):4406-14.
    22733536
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS.Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.Risk Anal. 2012 Jul;32 Suppl 1:S117-24.
    22882882
  • Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Cancer Imaging. 2012;12:225-35.
    22743083
  • Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.Imaging of lung cancer in the era of molecular medicine.Acad Radiol. 2011 Apr;18(4):424-36.
    21277232
  • Cooley ME, Emmons KM, Haddad R, Wang Q, Posner M, Bueno R, Cohen TJ, Johnson BE.Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer.Cancer. 2011 Jan 10.
    21225877
  • Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Acad Radiol. 2011 Jan;18(1):54-62.
    21036632
  • Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.Clin Cancer Res. 2010 Dec 1;16(23):5873-82.
    21030498
  • Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.AJR Am J Roentgenol. 2010 Sep;195(3):W221-8.
    20729419
  • Paulus JK, Zhou W, Kraft P, Johnson BE, Lin X, Christiani DC.Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.Lung Cancer. 2010 Jul 22.
    20655613
  • Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE.Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.Lancet Oncol. 2010 Jul;11(7):619-26.
    20570559
  • Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Jänne PA, Iafrate AJ, Rodig SJ.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Clin Cancer Res. 2010 Mar 1;16(5):1561-71.
    20179225
  • Barletta JA,Perner S,Iafrate AJ,Yeap BY,Weir BA,Johnson LA,Johnson BE,Meyerson M,Rubin MA,Travis WD,Loda M,Chirieac LR.Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung Adenocarcinoma.J Cell Mol Med. 2009 Aug;13(8B):1977-86.
    19040416
  • Paulus JK, Asomaning K, Kraft P, Johnson BE, Lin X, Christiani DC.Parity and risk of lung cancer in women.Am J Epidemiol. 2010 Mar 1;171(5):557-63.
    20123687
  • Johnson BE, Johnson CA.ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women.Ann Intern Med. 2010 Feb 16;152(4):JC-28.
    20157132
  • Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE, Heymach JV.Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):193-201.
    19949019
  • Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;28(2):357-60.
    19949011
  • Hammerman PS, Jänne PA, Johnson BE.Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Clin Cancer Res. 2009 Dec 15;15(24):7502-7509.
    20008850
  • Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM.Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.Cancer. 2009 Sep 15;115(18):4156-66.
    19551884
  • Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ.Integration of molecular profiling into the lung cancer clinic.Clin Cancer Res. 2009 Sep 1;15(17):5317-22.
    19706816
  • Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.J Thorac Oncol. 2009 Sep;4(9):1156-62.
    19704336
  • Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res. 2009 Aug 15;15(16):5216-23.
    19671850
  • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.Clin Cancer Res. 2009 Aug 15;15(16):5267-73.
    19671843
  • Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ.Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.J Thorac Cardiovasc Surg. 2009 Aug;138(2):405-11.
    19619785
  • Naumov GN,Nilsson MB,Cascone T,Briggs A,Straume O,Akslen LA,Lifshits E,Byers LA,Xu L,Wu HK,Janne P,Kobayashi S,Halmos B,Tenen D,Tang XM,Engelman J,Yeap B,Folkman J,Johnson BE,Heymach JV.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clin Cancer Res. 2009 May 15;15(10):3484-94.
    19447865
  • Hanrahan EO,Ryan AJ,Mann H,Kennedy SJ,Langmuir P,Natale RB,Herbst RS,Johnson BE,Heymach JV.Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clin Cancer Res. 2009 May 15;15(10):3600-9.
    19447868
  • Zellos L,Richards WG,Capalbo L,Jaklitsch MT,Chirieac LR,Johnson BE,Bueno R,Sugarbaker DJ.A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.J Thorac Cardiovasc Surg. 2009 Feb;137(2):453-8.
    19185169
  • McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS.Adopting helical CT screening for lung cancer : potential health consequences during a 15-year period.Cancer. 2008 Dec 15;113(12):3440-9.
    18988293
  • Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
    18980991
  • Ding L,Getz G,Wheeler DA,Mardis ER,McLellan MD,Cibulskis K,Sougnez C,Greulich H,Muzny DM,Morgan MB,Fulton L,Fulton RS,Zhang Q,Wendl MC,Lawrence MS,Larson DE,Chen K,Dooling DJ,Sabo A,Hawes AC,Shen H,Jhangiani SN,Lewis LR,Hall O,Zhu Y,Mathew T,Ren Y,Yao J,Scherer SE,Clerc K,Metcalf GA,Ng B,Milosavljevic A,Gonzalez-Garay ML,Osborne JR,Meyer R,Shi X,Tang Y,Koboldt DC,Lin L,Abbott R,Miner TL,Pohl C,Fewell G,Haipek C,Schmidt H,Dunford-Shore BH,Kraja A,Crosby SD,Sawyer CS,Vickery T,Sander S,Robinson J,Winckler W,Baldwin J,Chirieac LR,Dutt A,Fennell T,Hanna M,Johnson BE,Onofrio RC,Thomas RK,Tonon G,Weir BA,Zhao X,Ziaugra L,Zody MC,Giordano T,Orringer MB,Roth JA,Spitz MR,Wistuba II,Ozenberger B,Good PJ,Chang AC,Beer DG,Watson MA,Ladanyi M,Broderick S,Yoshizawa A,Travis WD,Pao W,Province MA,Weinstock GM,Varmus HE,Gabriel SB,Lander ES,Gibbs RA,Meyerson M,Wilson RK.Somatic mutations affect key pathways in lung adenocarcinoma.Nature. 2008 Oct 23;455(7216):1069-75.
    18948947
  • Heymach JV,Paz-Ares L,De Braud F,Sebastian M,Stewart DJ,Eberhardt WE,Ranade AA,Cohen G,Trigo JM,Sandler AB,Bonomi PD,Herbst RS,Krebs AD,Vasselli J,Johnson BE.Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.J Clin Oncol. 2008 Nov 20;26(33):5407-15.
    18936474
  • Dahlberg SE,Gray RJ,Johnson BE.Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.J Clin Oncol. 2008 Sep 10;26(26):4233-5.
    18779608
  • Saad AG,Yeap BY,Thunnissen FB,Pinkus GS,Pinkus JL,Loda M,Sugarbaker DJ,Johnson BE,Chirieac LR.Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.Cancer. 2008 Oct 15;113(8):2129-38.
    18720359
  • Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Br J Cancer. 2008 Jul 22;99(2):245-52.
    18594528
  • McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS.Estimating Long-term Effectiveness of Lung Cancer Screening in the Mayo CT Screening Study.Radiology. 2008 Jul;248(1):278-87.
    18458247
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.J Clin Oncol. 2008 May 20;26(15):2442-9.
    18458038
  • Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr.Small cell lung cancer.J Natl Compr Canc Netw. 2008 Mar;6(3):294-314.
    18377848
  • Eberhard DA, Giaccone G, Johnson BE.Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.J Clin Oncol. 2008 Feb 20;26(6):983-94. Review.
    18281673
  • Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M.Characterizing the cancer genome in lung adenocarcinoma.Nature. 2007 Dec 6;450(7171):893-8.
    17982442
  • Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE.Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.Clin Cancer Res. 2007 Oct 15;13(20):6175-81.
    17947484
  • Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spsov I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS.Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.J Clin Oncol. 2007 Sep 20;25(27):4270-7.
    17878479
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007 Aug 16;448(7155):807-10.
    17676035
  • Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Jnne PA, Johnson BE, Chin L, Wong KK.Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Cancer Res. 2007 May 15;67(10):4933-9.
    17510423
  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jnne PA.MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling.Science. 2007 May 18;316(5827):1039-43.
    17463250
  • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M.Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 world health organization pathologic criteria.J Thorac Oncol. 2006 Nov;1(9 Suppl):S13-9.
    17409995
  • Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.Cancer. 2007 Mar 1;109(5):924-32.
    17285598
  • Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jnne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.J Clin Oncol. 2007 Mar 1;25(7):760-6.
    17228019
  • Johnson BE, Jackman D, Jnne PA.Impact of EGFR mutations on treatment of non-small cell lung cancer.Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 7:5-9.
    17093938
  • Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrs AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jnne PA.Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer.J Clin Invest. 2006 Oct;116(10):2695-706.
    16906227
  • Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jnne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.J Clin Oncol. 2006 Sep 20;24(27):4517-20.
    16983123
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jnne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.Clin Cancer Res. 2006 Jul 15;12(14):4365s-71s.
    16857812
  • Johnson BE, Jnne PA.Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer.Clin Cancer Res. 2006 Jul 15;12(14):4436s-40s. Review.
    16857824
  • Jnne PA, Johnson BE.Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14):4416s-20s. Review.
    16857820
  • Sequist LV, Joshi VA, Jnne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer patients.Clin Cancer Res. 2006 Jul 15;12(14):4403s-8s. Review.
    16857818
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
    16818686
  • Gandhi L, Johnson BE.Paraneoplastic syndromes associated with small cell lung cancer.J Natl Compr Canc Netw. 2006 Jul;4(6):631-8. Review.
    16813730
  • Johnson BE, Crawford J, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Kalemkerian GP, Kessinger A, Koczywas M, Langer CJ, Martins R, Marymont MH, Niell HB, Ramnath N, Robert F, Williams CC,.Small cell lung cancer clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2006 Jul;4(6):602-22.
    16813728
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jnne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell. 2006 Jun;9(6):485-95.
    16730237
  • Chute JP, Taylor E, Williams J, Kaye F, Venzon D, Johnson BE.A metabolic study of patients with lung cancer and hyponatremia of malignancy.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):888-96.
    16467103
  • Jnne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8.
    16467085
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Raimes DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagri S, Hillan KJ.Mutations in the Epidermal Growth FActor Receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of Clinical Oncology.;In press.
  • Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris M, Klein P, Li Xin, Ramies D, Johnson DH, Miller V.Tribute - A Phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC).Journal of Clinical Oncology.;In press.
  • Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ,.Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2006 Jan 1;24(1):190-205.
    16326753
  • Myers JN, O'neil KM, Walsh TE, Hoffmeister KJ, Venzon DJ, Johnson BE.The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation.Chest. 2005 Nov;128(5):3261-8.
    16304271
  • Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jnne PA.Inhibition of the met receptor in mesothelioma.Clin Cancer Res. 2005 Nov 15;11(22):8122-30.
    16299245
  • Jackman DM, Johnson BE.Small-cell lung cancer.Lancet. 2005 Oct 15-21;366(9494):1385-96.
    16226617
  • Johnson BE, Jnne PA.Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.Cancer Res. 2005 Sep 1;65(17):7525-9.
    16140912
  • Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jnne PA.Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.
    16106023
  • Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA,.TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.J Clin Oncol. 2005 Sep 1;23(25):5892-9.
    16043829
  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Jnne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol. 2005 Sep 1;23(25):5900-9.
    16043828
  • Mukohara T, Civiello G, Johnson BE, Janne PA.Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.Oncology. 2005;68(4-6):500-10.
    16020981
  • Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C.Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):4981s-4983s.
    16000599
  • Johnson BE, Rabin MS.Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s.
    16000607
  • Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnisen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M.Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.J Clin Oncol. 2005 May 10;23(14):3279-87.
    15886315
  • Jnne PA, Engelman JA, Johnson BE.Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.J Clin Oncol. 2005 May 10;23(14):3227-34.
    15886310
  • Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Clin Cancer Res. 2005 May 1;11(9):3417-24.
    15867243
  • Engelman JA, Jnne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93.
    15731348
  • Kobayashi S, Boggon TJ, Dayaram T, Jnne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med. 2005 Feb 24;352(8):786-92.
    15728811
  • Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Jnne PA.Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.Cancer Res. 2004 Oct 15;64(20):7241-4.
    15492241
  • Heymach JV, Johnson DH, Khuri FR, Safran H, Schlabach LL, Yunus F, DeVore RF, De Porre PM, Richards HM, Jia X, Zhang S, Johnson BE.Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.Ann Oncol. 2004 Aug;15(8):1187-93.
    15277257
  • Johnson BE, Heymach JV.Farnesyl transferase inhibitors for patients with lung cancer.Clin Cancer Res. 2004 Jun 15;10(12):4254S-7S.
    15217969
  • Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS.Novel agents in the treatment of lung cancer: conference summary statement.Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4199s-4204s.
    15217958
  • Paez JG, Jnne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy.Science. 2004 Jun 4;304(5676):1497-500.
    15118125
  • Johnson BE.Imatinib for small cell lung cancer, aiming for a target in vivo.Clin Cancer Res. 2004 May 15;10(10):3235-6.
    15161675
  • Johnson BE, Jnne PA.Basic treatment considerations using chemotherapy for patients with small cell lung cancer.Hematol Oncol Clin North Am. 2004 Apr;18(2):309-22.
    15094173
  • Jnne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE.Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.Lung Cancer. 2004 May;44(2):221-30.
    15084387
  • Wirth LJ, Carter MR, Jnne PA, Johnson BE.Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.Lung Cancer. 2004 May;44(2):213-20.
    15084386
  • Jnne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M.High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines.Oncogene. 2004 Apr 8;23(15):2716-26.
    15048096
  • Cross CK, Berman S, Buswell L, Johnson B, Baldini EH.Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1098-105.
    15001250
  • Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T.Phase II study of imatinib in patients with small cell lung cancer.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7.
    14676110
  • Means-Markwell M, Linnoila RI, Williams J, Jnne PA, Kaye F, O'Neil K, Johnson BE.Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer.Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5915-21.
    14676115
  • Johnson BE.Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning.J Natl Cancer Inst. 2003 Oct 1;95(19):1422-4.
    14519741
  • Soria JC, Johnson BE, Chevalier TL.Imatinib in small cell lung cancer.Lung Cancer. 2003 Aug;41 Suppl 1:S49-53.
    12867062
  • Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC.Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma.Cancer. 2003 Jul 1;98(1):135-43.
    12833466
  • Fujishita T, Loda M, Turner RE, Gentler M, Kashii T, Breathnach OS, Johnson BE.Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.Oncology. 2003;64(4):399-406.
    12759538
  • Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jnne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT.Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.Clin Cancer Res. 2003 May;9(5):1698-704.
    12738723
  • Freidlin B, Breathnach OS, Johnson BE.A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.Clin Cancer Res. 2003 Mar;9(3):917-22.
    12631588
  • Kijima T, Maulik G, Ma PC, Tibaldi EV, Turner RE, Rollins B, Sattler M, Johnson BE, Salgia R.Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.Cancer Res. 2002 Nov 1;62(21):6304-11.
    12414661
  • Jnne PA, Freidlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA, Johnson BE.Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Cancer. 2002 Oct 1;95(7):1528-38.
    12237922
  • Jnne PA, Taffaro ML, Salgia R, Johnson BE.Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.Cancer Res. 2002 Sep 15;62(18):5242-7.
    12234991
  • Breathnach OS, Kasturi V, Kaye F, Herscher L, Georgiadis MS, Edison M, Schuler BS, Pizzella P, Steinberg SM, O'Neil K, Johnson BE.Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer.Am J Clin Oncol. 2002 Jun;25(3):269-73.
    12040286
  • Johnson BE.Management of small cell lung cancer.Clin Chest Med. 2002 Mar;23(1):225-39.
    11901913
  • Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.Clin Cancer Res. 2002 Feb;8(2):620-7.
    11839685
  • Johnson BE,.NCCN: Small cell lung cancer.Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):32-43.
    11760556
  • Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ.A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):3942-9.
    11751486
  • Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5.
    11707567
  • Jnne PA, Rodriguez-Thompson D, Metcalf DR, Swanson SJ, Greisman HA, Wilkins-Haug L, Johnson BE.Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy.Oncology. 2001;61(3):175-83.
    11574771
  • Johnson BE, Johnson CA.Cardiovascular disease and differences between the sexes.Am Fam Physician. 2001 Apr 1;63(7):1290, 1292.
    11310645
  • Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE.Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.J Clin Oncol. 2001 Mar 15;19(6):1734-42.
    11251004
  • Johnson BE.Is more better? Chemotherapy for patients with extensive-stage small-cell lung cancer.J Natl Cancer Inst. 2001 Feb 21;93(4):254-5.
    11181764
  • Breathnach OS, Kwiatkowski DJ, Finkelstein DM, Godleski J, Sugarbaker DJ, Johnson BE, Mentzer S.Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.J Thorac Cardiovasc Surg. 2001 Jan;121(1):42-7.
    11135158
  • Johnson BE, Mentzer S.Broncholoalveolar carcinoma of the lung: Recurrences and survival in patients with stage I disease.Harrison's Principles of Internal Medicine. 2001 Jan;121(1):42-47.
  • Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE, Lander ES, Meyerson M.Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays.Nat Biotechnol. 2000 Sep;18(9):1001-5.
    10973224
  • Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, Feld R, Shepherd FA, Johnson DH, Grant SC, Aisner J, Johnson BE.Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre.J Natl Cancer Inst. 1997 Dec 3;89(23):1782-8.
    9392619